Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Zenas BioPharma director acquires $999k in company stock | 1 | Investing.com | ||
Di | IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx | 2 | The Armchair Trader | ||
Di | Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock | 1 | Investing.com | ||
Di | Zenas BioPharma director buys $7.48m in company stock | 1 | Investing.com | ||
Di | Zenas BioPharma director Jason Raleigh acquires $15 million in company stock | 4 | Investing.com | ||
Di | SR One Capital management buys $38m of Zenas BioPharma stock | 2 | Investing.com | ||
Mo | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
Mo | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Fr | Zenas BioPharma shares rise nearly 8% in market debut | 1 | Reuters | ||
Fr | Immunology biotech Zenas BioPharma prices upsized IPO at $17 midpoint | 2 | Renaissance Capital | ||
Fr | Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs | - | FierceBiotech | ||
Fr | Zenas BioPharma prices $225M IPO at $17 per share | 1 | Seeking Alpha | ||
Fr | Zenas BioPharma raises $225 million in US IPO | 1 | Reuters | ||
Fr | Zenas BioPharma Announces Pricing of Upsized Initial Public Offering | 282 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen | |
10.09. | Zenas BioPharma, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
06.09. | Immunology biotech Zenas BioPharma sets terms for $200 million IPO | 1 | Renaissance Capital | ||
06.09. | Zenas BioPharma Prices 11.76 Mln IPO At $16 - $18/share | 547 | AFX News | WASHINGTON (dpa-AFX) - Zenas BioPharma, Inc. announced on Friday its intention to offer 11.76 million shares priced between $16 and $18 each for its Initial Public Offering. The company has... ► Artikel lesen | |
06.09. | Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 million valuation in US IPO | 19 | Reuters | ||
06.09. | Zenas BioPharma Files for 11.76M Share IPO at $16-$18/sh | 1 | Investing.com | ||
06.09. | Zenas BioPharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PORTAGE BIOTECH | 9,850 | 0,00 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
QIAGEN | 41,190 | -0,95 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 54,90 Euro auf "Buy" belassen. Medizintechnik-Unternehmen seien nach dem schwachen Vorjahr... ► Artikel lesen | |
BIONTECH | 104,10 | -7,22 % | BioNTech, First Hydrogen und TSMC mit Paukenschlägen | Das letzte Drittel des bislang erfolgreichen Börsenjahres 2024 läuft, doch die Unsicherheiten und Volatilitäten nehmen zu. So verlor der noch bis vor kurzem als unverwundbar geltende Chipgigant Nvidia... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 24,550 | 0,00 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
ADMA BIOLOGICS | 19,300 | +3,18 % | ADMA Biologics, Inc.: ADMA Biologics Set to Join S&P SmallCap 600 Index | RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,620 | 0,00 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
EVOTEC | 6,460 | -0,39 % | Bayer, BMW, Deutsche Bank, Evotec, Rheinmetall - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MODERNA | 62,95 | -2,82 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Moderna, Ryanair, Adobe, Fraport und Baloise | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 53,21 | 0,00 % | Moonlake Immunotherapeutics behält Buy-Bewertung aufgrund von HS- und PsA-Potenzial | ||
EDGEWISE THERAPEUTICS | 19,040 | 0,00 % | Edgewise präsentiert Daten aus Phase-1- und -2-Studien für Herzmedikament | ||
NUVALENT | 102,76 | 0,00 % | Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? | ||
ARRIVENT BIOPHARMA | 23,580 | -1,75 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2024 Financial Results | Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,900 | 0,00 % | Looking Into Recursion Pharmaceuticals' Recent Short Interest | ||
ARCELLX | 80,55 | 0,00 % | Arcellx CFO Michelle Gilson sells shares worth over $1.1 million | ||
LONGBOARD PHARMACEUTICALS | 29,310 | +6,74 % | Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target |